Matches in SemOpenAlex for { <https://semopenalex.org/work/W3062204540> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3062204540 abstract "Introduction: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by progressive cell death in the substantia nigra portion of the midbrain, which results in severe dopamine imbalance and a subsequent loss of refined motor control. Pathogenicity arises from mutations driving the misfolding of alpha synuclein (ɑ-syn), thus leading to oligomerization and formation of Lewy body aggregates in neurons. Previous research has identified the A30P mutated oligomers, which are connected to familial early-onset PD, as particularly toxic intermediates. However, there are insufficient methods of targeting them in isolation of other forms of the ɑ-syn protein. We aim to modify existing approaches to immunotherapy of PD, by use of CRISPR-X and phage display, to design antibodies that are highly specific to the A30P oligomer.Methods: We will use CRISPR-X to produce a diverse library of antibodies by introducing point mutations in the sequences encoding their variable light (VL) and heavy (VH) chains. Then, via insertion into bacteriophages for multiple rounds of phage display selection, we should obtain a polyclonal selection of antibodies that exclusively recognize epitopes on A30P ɑ-syn. Each variant then produces a distinct monoclonal phage colony to be incubated with relevant antigens for affinity testing via enzyme-linked immunosorbent assay (ELISA).Expected Results: We expect that measurements from ELISA would indicate low dissociation constants (KD) within the low micromolar (10-6) to nanomolar (10-7 to 10-9) range, when incubated with A30P oligomers. We predict that the resultant antibodies would have a higher affinity for the A30P oligomeric ɑ-syn than other forms of the protein. Furthermore, the novel antibodies are expected to have a higher specificity to this target antigen than the original antibodies that were modified.Discussion: By determining binding affinity, we verify the effectiveness of this method for improving specificity of in vitro antibody design. Upon further investigation using mice models, we would anticipate these novel antibodies could produce a specific reversal of the toxic effects of A30P in neuronal tissue.Conclusion: This study aims to establish a potential for CRISPR-X and phage selection to be used in antibody optimization for developing an immunotherapeutic treatment for PD." @default.
- W3062204540 created "2020-08-24" @default.
- W3062204540 creator A5043404529 @default.
- W3062204540 creator A5076980667 @default.
- W3062204540 date "2020-08-17" @default.
- W3062204540 modified "2023-09-27" @default.
- W3062204540 title "Using CRISPR-X for Optimization of Antibodies Towards A30P α-synuclein Oligomers in Immunotherapy of Parkinson’s Disease" @default.
- W3062204540 doi "https://doi.org/10.26685/urncst.188" @default.
- W3062204540 hasPublicationYear "2020" @default.
- W3062204540 type Work @default.
- W3062204540 sameAs 3062204540 @default.
- W3062204540 citedByCount "0" @default.
- W3062204540 crossrefType "journal-article" @default.
- W3062204540 hasAuthorship W3062204540A5043404529 @default.
- W3062204540 hasAuthorship W3062204540A5076980667 @default.
- W3062204540 hasBestOaLocation W30622045401 @default.
- W3062204540 hasConcept C121608353 @default.
- W3062204540 hasConcept C142724271 @default.
- W3062204540 hasConcept C159654299 @default.
- W3062204540 hasConcept C178790620 @default.
- W3062204540 hasConcept C185592680 @default.
- W3062204540 hasConcept C186268636 @default.
- W3062204540 hasConcept C195616568 @default.
- W3062204540 hasConcept C2777701055 @default.
- W3062204540 hasConcept C2779134260 @default.
- W3062204540 hasConcept C2779734285 @default.
- W3062204540 hasConcept C2780632150 @default.
- W3062204540 hasConcept C2780642029 @default.
- W3062204540 hasConcept C2781449126 @default.
- W3062204540 hasConcept C542903549 @default.
- W3062204540 hasConcept C54355233 @default.
- W3062204540 hasConcept C71924100 @default.
- W3062204540 hasConcept C86803240 @default.
- W3062204540 hasConcept C956191 @default.
- W3062204540 hasConceptScore W3062204540C121608353 @default.
- W3062204540 hasConceptScore W3062204540C142724271 @default.
- W3062204540 hasConceptScore W3062204540C159654299 @default.
- W3062204540 hasConceptScore W3062204540C178790620 @default.
- W3062204540 hasConceptScore W3062204540C185592680 @default.
- W3062204540 hasConceptScore W3062204540C186268636 @default.
- W3062204540 hasConceptScore W3062204540C195616568 @default.
- W3062204540 hasConceptScore W3062204540C2777701055 @default.
- W3062204540 hasConceptScore W3062204540C2779134260 @default.
- W3062204540 hasConceptScore W3062204540C2779734285 @default.
- W3062204540 hasConceptScore W3062204540C2780632150 @default.
- W3062204540 hasConceptScore W3062204540C2780642029 @default.
- W3062204540 hasConceptScore W3062204540C2781449126 @default.
- W3062204540 hasConceptScore W3062204540C542903549 @default.
- W3062204540 hasConceptScore W3062204540C54355233 @default.
- W3062204540 hasConceptScore W3062204540C71924100 @default.
- W3062204540 hasConceptScore W3062204540C86803240 @default.
- W3062204540 hasConceptScore W3062204540C956191 @default.
- W3062204540 hasLocation W30622045401 @default.
- W3062204540 hasOpenAccess W3062204540 @default.
- W3062204540 hasPrimaryLocation W30622045401 @default.
- W3062204540 hasRelatedWork W16108654 @default.
- W3062204540 hasRelatedWork W19835385 @default.
- W3062204540 hasRelatedWork W20034035 @default.
- W3062204540 hasRelatedWork W20044489 @default.
- W3062204540 hasRelatedWork W370594 @default.
- W3062204540 hasRelatedWork W4143400 @default.
- W3062204540 hasRelatedWork W4681189 @default.
- W3062204540 hasRelatedWork W5014870 @default.
- W3062204540 hasRelatedWork W7586533 @default.
- W3062204540 hasRelatedWork W824099 @default.
- W3062204540 isParatext "false" @default.
- W3062204540 isRetracted "false" @default.
- W3062204540 magId "3062204540" @default.
- W3062204540 workType "article" @default.